Literature DB >> 7075111

Phencyclidine disposition after intravenous and oral doses.

C E Cook, D R Brine, A R Jeffcoat, J M Hill, M E Wall, M Perez-Reyes, S R Di Guiseppi.   

Abstract

[3H]-Phencyclidine (PCP) hydrochloride was given in intravenous (0.1 or 1 mg) or oral (1 mg) doses to male subjects. After 1 mg IV, drug and metabolites were recovered in urine (72.8 +/- 4.0% of dose), feces (4.7 +/- 0.9%), and perspiration. Fecal excretion was low (3.4 +/- 0.4%) after oral dosing and oral bioavailability was estimated at 72%. PCP comprised 16% of urinary radioactivity with 31% consisting of enzymatically hydrolyzable conjugates of hydroxylated metabolites. Both cis and trans isomers of 4-phenyl-4-(1-piperidinyl)cyclohexanol were found. Maximum average plasma PCP concentrations of 2.7 to 2.9 ng/ml were observed after oral and intravenous 1-mg doses. Blood/plasma ratios were approximately 1.0 and plasma binding was about 65%. Parent drug was found in saliva. Apparent terminal phase half-lifes averaged 21 +/- 3 hr (harmonic mean 17 hr, range 7 to 46 hr). The volume of distribution averaged 6.2 +/- 0.3 l/kg. Renal clearances were variable, but the average was 9% of the total clearance. Thus, PCP is cleared principally by metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075111     DOI: 10.1038/clpt.1982.87

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 2.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  Simple and sensitive detection of phencyclidine in body fluids by gas chromatography with surface ionization detection.

Authors:  A Ishii; H Seno; T Kumazawa; M Nishikawa; K Watanabe; O Suzuki
Journal:  Int J Legal Med       Date:  1996       Impact factor: 2.686

Review 4.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

5.  Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug.

Authors:  Tareg Bey; Anar Patel
Journal:  Cal J Emerg Med       Date:  2007-02

Review 6.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.